601607.SH
Shanghai Pharmaceuticals Holding Co., Ltd.
SSE · Healthcare · Medical - Distribution · CN
CNY 16.19
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 289.1B | 283.6B | 275.3B | 260.3B | 232.0B |
| Cost of Revenue | 257.9B | 253.2B | 244.6B | 229.0B | 201.5B |
| Gross Profit | 31.2B | 30.4B | 30.6B | 31.3B | 30.5B |
| Operating Expenses | |||||
| R&D Expense | 1.8B | 2.3B | 2.4B | 2.2B | 2.1B |
| SG&A Expense | (69.0M) | — | — | — | — |
| General & Admin Expense | 3.3B | 5.3B | 5.7B | 5.7B | 5.0B |
| Selling & Marketing Expense | 10.9B | 13.2B | 12.7B | 13.9B | 14.3B |
| Other Expenses | 5.2B | — | — | — | — |
| Total Operating Expenses | 22.9B | 23.1B | 23.1B | 24.0B | 23.4B |
| Cost and Expenses | 280.8B | 276.3B | 267.7B | 253.0B | 224.9B |
| Operating Income (EBIT) | 8.1B | 9.9B | 8.1B | 7.7B | 9.0B |
| Non-Operating | |||||
| Interest Income | 889.8M | — | — | — | — |
| Interest Expense | 356.9M | — | — | — | — |
| Net Interest Income | 533.0M | — | — | — | — |
| Other Non-Op Income/Expense | 643.5M | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 8.6B | 9.8B | 8.0B | 7.1B | 8.8B |
| Income Tax Expense | 2.3B | 2.8B | 2.1B | 1.9B | 1.8B |
| Bottom Line | |||||
| Net Income | 4.8B | 5.7B | 4.6B | 3.8B | 5.6B |
| Earnings from Cont. Ops | 6.3B | 7.0B | 5.9B | 5.2B | 7.0B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 4.8B | 5.7B | 4.6B | 3.8B | 5.6B |
| Per Share | |||||
| Basic EPS | CN¥1.28 | CN¥1.54 | CN¥1.23 | CN¥1.02 | CN¥1.61 |
| Diluted EPS | CN¥1.28 | CN¥1.54 | CN¥1.23 | CN¥1.02 | CN¥1.61 |
| Revenue Per Share | CN¥77.97 | CN¥76.29 | CN¥74.37 | CN¥70.46 | CN¥66.49 |
| Shares | |||||
| Basic Shares Outstanding | 3.7B | 3.7B | 3.7B | 3.7B | 3.5B |
| Diluted Shares Outstanding | 3.7B | 3.7B | 3.7B | 3.7B | 3.5B |
| Profitability Metrics | |||||
| EBITDA | 2.6B | 12.3B | 10.0B | 9.4B | 10.7B |
| D&A | — | 2.3B | 1.9B | 1.7B | 1.7B |
| EBIT | 2.6B | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026